A soluble transforming growth factor β receptor expressed in muscle prevents liver fibrogenesis and dysfunction in rats

Human Gene Therapy

Volumn 11, Issue 1, 2000, Pages 33-42

  Ueno, Hikaru ^a   Sakamoto, Taiji ^a   Nakamura, Toru ^a   Qi, Zhe ^a   Astuchi, Nobuhiko ^a   Takeshita, Akira ^a   Shimizu, Kiyoshi ^b   Ohashi, Hideya ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b KIRIN BREWERY CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ADENOVIRUS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FIBROGENESIS; GENE THERAPY; GENE TRANSFER; LIVER DISEASE; LIVER FIBROSIS; NONHUMAN; SKELETAL MUSCLE; VIRUS REPLICATION;

ANIMALS; DIMETHYLNITROSAMINE; GENE THERAPY; INJECTIONS, INTRAMUSCULAR; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MUSCLE, SKELETAL; RATS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION;

EID: 0033984336     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340050016139     Document Type: Article

References (29)

1. Abe, M., Harpel, J.G., Metz, C.N., Nunes, I., Loskutoff, D.J., and Rifkin, D.B. (1994). An assay for transforming growth factor-β using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal. Biochem. 216, 276-284.
2. Aiello, L.P., Pierce, E.A., Foley, E.D., Takagi, H., Chen, H., Riddle, L., Ferrara, N., King, G.L., and Smith, L.E.H. (1995). Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. U.S.A. 92, 10457-10461.
3. Border, W.A., and Noble, N.A. (1994). Transforming growth factor β in tissue fibrosis. N. Engl. J. Med. 331, 1286-1292.
4. Friedman, S.L. (1993). The cellular basis of hepatic fibrosis. N. Engl. J. Med. 328, 1828-1835.
5. Friedman, S.L., Yamasaki, G., and Wong, L. (1994). Modulation of transforming growth factor β receptors of rat lipocytes during the hepatic wound healing response. J. Biol. Chem. 269, 10551-10558.
6. Isaka, Y., Brees, D.K., Ikegaya, K., Kaneda, Y., Imai, E., Noble, N.A., and Border, W.A. (1996). Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nature Med. 2, 418-423.
7. Jenkins, S.A., Grandison, A., Bazter, J.N., Day, D.W., Taylor, I., and Shields, R. (1985). A dimethylnitrosamine-induced model of cirrhosis and portal hypertension in the rat. J. Hepatol. 1, 489-499.
8. Jezequel, A.M., Mancini, R., Rinaldesi, M.L., Macarri, G., Venturini, C., and Orlandi, F. (1987). A morphological study of the early stages of hepatic fibrosis induces by low doses of dimethylnitrosamine in the rat. J. Hepatol. 5, 174-181.
9. Kendall, R.L., and Thomas, K.A. (1993). Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. U.S.A. 90, 10705-10709.
10. Kendall, R.L., Wang, G., and Thomas, K.A. (1996). Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem. Biophys. Res. Commun. 226, 324-328.
11. Kozarsky, K.F., McKinley, D.R., Austin, L.L., Raper, S.E., Stratford-Perricaudet, L.D., and Wilson, J.M. (1994). In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J. Biol. Chem. 269, 13695-13702.
12. Kumagai, J., Sarkar, K., Uhthoff, H.K., Okawara, Y., and Ooshima, A. (1994). Immunohistochemical distribution type I, II, and III collagens in the rabbit supraspinatus tendon insertion. J. Anat. 185, 279-284.
13. Li, Q., Kay, M.A., Finegold, M., Stradford-Perricaudet, L.D., and Woo, S.L.C. (1993). Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum. Gene Ther. 4, 403-409.
14. Lin, P., Buxton, J.A., Acheson, A., Radziejewski, C., Maisonpierre, P.C., Yancopoulos, G.D., Channon, K.M., Hale, L.P., Dewhirst, M.W., George, S.E., and Peters, K.G. (1998a). Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc. Natl. Acad. Sci. U.S.A. 95, 8829-8834.
15. Lin, P., Sankar, S., Shan, S., Dewhirst, M.W., Polverini, P.J., Quinn, T.Q., and Peters, K.G. (1998b). Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Different. 9, 49-58.
16. Liu, Y.-C., Kawagishi, M., Kameda, R., and Ohashi, H. (1993a). Characterization of a fusion protein composed of the extracellular domain of c-kit and the Fc region of human IgG expressed in a baculovirus system. Biochem. Biophys. Res. Commun. 197, 1094-1102.
17. Liu, Y.-C., Kawagishi, T., Mikayama, T., Inagaki, Y., Takeuchi, T., and Ohashi, H. (1993b). Processing of a fusion protein by endoprotease in Cos-1 cells for secretion of mature peptide by using a chimeric expression vector. Proc. Natl. Acad. Sci. U.S.A. 90, 8957-8961.
18. Massague, J. (1990). The transforming growth factor-β family. Annu. Rev. Cell Biol. 6, 597-641.
19. Miyake, S., Makimura, M., Kanegae, Y., Harada, S., Sato, Y., Takamori, K., Tokuda, C., and Saito, I. (1996). Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc. Natl. Acad. Sci. U.S.A. 93, 1320-1324.
20. Niwa, H., Yamamura, K., and Miyazaki, J. (1991). Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108, 193-200.
21. Park, L., Raman, K.G., Lee, K.J., Lu, Y., Ferran, L.J.J., Chow, W.S., Stern, D., and Schmidt, A.M. (1998). Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nature Med. 4, 1025-1031.
22. Qi, Z., Atsuchi, N., Ooshima, A., Takeshita, A., and Ueno, H. (1999). Blockade of TGF-β signaling prevents liver fibrosis and dysfunction in the rats. Proc. Natl. Acad. Sci. U.S.A. 96, 2345-2349.
23. Shull, M.M., Ormsby, I., Kier, A.B., Pawlowski, S., Diebold, R.J., Yin, M., Allen, R., Sidman, C., Proetzel, G., Calvin, D., Annunziata, N., and Doetschman, T. (1992). Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature (London) 359, 693-699.
24. Sporn, M.B., and Roberts, A.B. (1992). Transforming growth factor-β: Recent progress and new challenges. J. Cell Biol. 119, 1017-1021.
25. Ueno, H., Li, J.-J., Tomita, H., Yamamoto, H., Pan, Y., Kanegae, Y., Saito, I., and Takeshita, A. (1995). Quantitative analysis of repeated adenovirus-mediated gene transfer into injured canine femoral arteries. Arterioscl. Thromb. Vasc. Biol. 15, 2246-2253.
26. Woessner, J.F.J. (1961). The determination of hydroxyproline in tissue and protein samples containing small amounts of the amino acid. Arch. Biochem. Biophys. 93, 440-447.
27. Wrana, J.L., Attisano, L., Carcamo, J., Zentella, J., Doody, J., Laiho, M., Wang, X-F., and Massague, J. (1992). TGF-β signals through a heterometric protein kinase receptor complex. Cell 71, 1003-1014.
28. Wrana, J.L., Attisano, L., Wieser, R., Ventura, F., and Massague, J. (1994). Mechanism of activation of the TGF-β receptor. Nature (London) 370, 341-347.
29. Yamamoto, H., Ueno, H., Ooshima, A., and Takeshita, A. (1996). Adenovirus-mediated transfer of a truncated transforming growth factor (TGF)-β type II receptor completely and specifically abolishes diverse signaling by TGF-β in vascular wall cells in primary culture. J. Biol. Chem. 271, 16253-16259.